,statement_id,standardized_cancer,raw_cancer,modified_standardized_cancer,biomarker,therapy,prompt
0,0,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Tamoxifen', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
1,1,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Tamoxifen', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
2,2,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Tamoxifen', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
3,3,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
4,4,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
5,5,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
6,6,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
7,7,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Abemaciclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
8,8,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
9,9,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
10,10,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
11,11,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
12,12,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Abemaciclib'],"if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
13,13,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Abemaciclib'],"if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
14,14,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Abemaciclib'],"if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
15,15,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 oncogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has bard1 oncogenic variants, what therapy is recommended?"
16,16,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 oncogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brip1 oncogenic variants, what therapy is recommended?"
17,17,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 pathogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brip1 pathogenic variants, what therapy is recommended?"
18,18,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],"['Prednisone', 'Niraparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has cdk12 pathogenic variants, what therapy is recommended?"
19,19,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['KRAS p.G12C'],['Adagrasib'],"if a patient with locally advanced or metastatic non-small cell lung cancer cancer has kras p.g12c, what therapy is recommended?"
20,20,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],['Trastuzumab emtansine'],"if a patient with metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
21,21,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],['Trastuzumab emtansine'],"if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
22,22,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR somatic variants'],['Afatinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr somatic variants, what therapy is recommended?"
23,23,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ALK'],['Alectinib'],"if a patient with non-small cell lung cancer cancer has v::alk, what therapy is recommended?"
24,24,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Alectinib'],"if a patient with metastatic non-small cell lung cancer cancer has v::alk, what therapy is recommended?"
25,25,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, pik3ca somatic variants, what therapy is recommended?"
26,26,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, pik3ca somatic variants, what therapy is recommended?"
27,27,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Alpelisib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, pik3ca somatic variants, what therapy is recommended?"
28,28,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']","if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 20 (insertion), what therapy is recommended?"
29,29,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Amivantamab'],"if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 20 (insertion), what therapy is recommended?"
30,30,APL with PML-RARA,low-risk acute promyelocytic leukemia (APL),low-risk apl with pml-rara,['PML::RARA'],['Arsenic trioxide'],"if a patient with low-risk apl with pml-rara cancer has pml::rara, what therapy is recommended?"
31,31,APL with PML-RARA,acute promyelocytic leukemia (APL),apl with pml-rara,['PML::RARA'],['Arsenic trioxide'],"if a patient with apl with pml-rara cancer has pml::rara, what therapy is recommended?"
32,32,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Asciminib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
33,33,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),philadelphia chromosome-positive chronic myelogenous leukemia,"['ABL1 p.T315I', 'BCR::ABL1']",['Asciminib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has abl1 p.t315i, bcr::abl1, what therapy is recommended?"
34,34,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['PD-L1 >= 1%'],['Atezolizumab'],"if a patient with non-small cell lung cancer cancer has pd-l1 >= 1%, what therapy is recommended?"
35,35,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 50%'],['Atezolizumab'],"if a patient with metastatic non-small cell lung cancer cancer has pd-l1 >= 50%, what therapy is recommended?"
36,36,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 10% TIIC'],['Atezolizumab'],"if a patient with metastatic non-small cell lung cancer cancer has pd-l1 >= 10% tiic, what therapy is recommended?"
37,37,Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Atezolizumab']","if a patient with metastatic non-squamous non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
38,38,Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Atezolizumab']","if a patient with metastatic non-squamous non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
39,39,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR somatic variants'],['Atezolizumab'],"if a patient with metastatic non-small cell lung cancer cancer has egfr somatic variants, what therapy is recommended?"
40,40,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Atezolizumab'],"if a patient with metastatic non-small cell lung cancer cancer has v::alk, what therapy is recommended?"
41,41,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Vemurafenib', 'Cobimetinib', 'Atezolizumab']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
42,42,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Vemurafenib', 'Cobimetinib', 'Atezolizumab']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600k, what therapy is recommended?"
43,43,Gastrointestinal Stromal Tumor,unresectable or metastatic GIST,unresectable or metastatic gastrointestinal stromal tumor,['PDGFRA p.D842V'],['Avapritinib'],"if a patient with unresectable or metastatic gastrointestinal stromal tumor cancer has pdgfra p.d842v, what therapy is recommended?"
44,44,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
45,45,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Binimetinib', 'Encorafenib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600k, what therapy is recommended?"
46,46,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']","if a patient with metastatic non-small cell lung cancer cancer has braf p.v600e, what therapy is recommended?"
47,47,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
48,48,Acute Lymphoid Leukemia,b-cell precursor acute lymphoblastic leukemia (ALL),b-cell precursor acute lymphoid leukemia,['CD19 +'],['Blinatumomab'],"if a patient with b-cell precursor acute lymphoid leukemia cancer has cd19 +, what therapy is recommended?"
49,49,Acute Lymphoid Leukemia,b-cell precursor acute lymphoblastic leukemia (ALL),b-cell precursor acute lymphoid leukemia,['CD19 +'],['Blinatumomab'],"if a patient with b-cell precursor acute lymphoid leukemia cancer has cd19 +, what therapy is recommended?"
50,50,Acute Lymphoid Leukemia,b-cell precusor acute lymphoblastic leukemia (ALL),b-cell acute lymphoid leukemia,"['BCR::ABL1', 'CD19 +']",['Blinatumomab'],"if a patient with b-cell acute lymphoid leukemia cancer has bcr::abl1, cd19 +, what therapy is recommended?"
51,51,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myelogenous leukemia (CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Bosutinib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
52,52,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myelogenous leukemia (CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Bosutinib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
53,54,Anaplastic Large Cell Lymphoma,"systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified",systemic anaplastic large cell lymphoma,['CD30 +'],"['Doxorubicin', 'Prednisone', 'Brentuximab vedotin', 'Cyclophosphamide']","if a patient with systemic anaplastic large cell lymphoma cancer has cd30 +, what therapy is recommended?"
54,55,Anaplastic Large Cell Lymphoma,cutaneous analastplci large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF),cutaneous anaplastic large cell lymphoma,['CD30 +'],['Brentuximab vedotin'],"if a patient with cutaneous anaplastic large cell lymphoma cancer has cd30 +, what therapy is recommended?"
55,56,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Brigatinib'],"if a patient with metastatic non-small cell lung cancer cancer has v::alk, what therapy is recommended?"
56,57,Adenocarcinoma of the Gastroesophageal Junction,metastatic gastric or gastroesophageal junction adenocarcinoma,metastatic adenocarcinoma of the gastroesophageal junction,['HER2-positive'],['Capecitabine'],"if a patient with metastatic adenocarcinoma of the gastroesophageal junction cancer has her2-positive, what therapy is recommended?"
57,58,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, pik3ca somatic variants, what therapy is recommended?"
58,59,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, pik3ca somatic variants, what therapy is recommended?"
59,60,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, pik3ca somatic variants, what therapy is recommended?"
60,61,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 somatic variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has akt1 somatic variants, her2-negative, er positive, what therapy is recommended?"
61,62,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'AKT1 somatic variants', 'HER2-negative']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, akt1 somatic variants, her2-negative, what therapy is recommended?"
62,63,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'AKT1 somatic variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, akt1 somatic variants, her2-negative, er positive, what therapy is recommended?"
63,64,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has akt1 amplification, her2-negative, er positive, what therapy is recommended?"
64,65,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has akt1 amplification, pr positive, her2-negative, what therapy is recommended?"
65,66,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['AKT1 amplification', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has akt1 amplification, pr positive, her2-negative, er positive, what therapy is recommended?"
66,67,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten nonsense variants, her2-negative, er positive, what therapy is recommended?"
67,68,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten nonsense variants, pr positive, her2-negative, what therapy is recommended?"
68,69,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN nonsense variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten nonsense variants, pr positive, her2-negative, er positive, what therapy is recommended?"
69,70,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten frameshift variants, her2-negative, er positive, what therapy is recommended?"
70,71,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten frameshift variants, pr positive, her2-negative, what therapy is recommended?"
71,72,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN frameshift variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten frameshift variants, pr positive, her2-negative, er positive, what therapy is recommended?"
72,73,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten splice site variants, her2-negative, er positive, what therapy is recommended?"
73,74,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'PR positive', 'HER2-negative']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten splice site variants, pr positive, her2-negative, what therapy is recommended?"
74,75,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PTEN splice site variants', 'PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pten splice site variants, pr positive, her2-negative, er positive, what therapy is recommended?"
75,76,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, pten deletion, what therapy is recommended?"
76,77,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, pten deletion, what therapy is recommended?"
77,78,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PTEN deletion']","['Fulvestrant', 'Capivasertib']","if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, pten deletion, what therapy is recommended?"
78,79,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['MET Exon 14 (Splice Site)'],['Capmatinib'],"if a patient with metastatic non-small cell lung cancer cancer has met exon 14 (splice site), what therapy is recommended?"
79,80,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['MET Exon 14 (Deletion)'],['Capmatinib'],"if a patient with metastatic non-small cell lung cancer cancer has met exon 14 (deletion), what therapy is recommended?"
80,81,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'Wild type ROS1']","['Carboplatin', 'Cemiplimab', 'Pemetrexed']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, wild type ros1, what therapy is recommended?"
81,82,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['dMMR', 'Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 50%']",['Cemiplimab'],"if a patient with non-small cell lung cancer cancer has dmmr, wild type egfr, wild type alk, pd-l1 >= 50%, what therapy is recommended?"
82,83,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Ceritinib'],"if a patient with metastatic non-small cell lung cancer cancer has v::alk, what therapy is recommended?"
83,84,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']","['Fluorouracil', 'Irinotecan', 'Cetuximab']","if a patient with metastatic colorectal adenocarcinoma cancer has egfr positive, wild type kras, what therapy is recommended?"
84,85,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']","['Irinotecan', 'Cetuximab']","if a patient with metastatic colorectal adenocarcinoma cancer has egfr positive, wild type kras, what therapy is recommended?"
85,86,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['EGFR positive', 'Wild type KRAS']",['Cetuximab'],"if a patient with metastatic colorectal adenocarcinoma cancer has egfr positive, wild type kras, what therapy is recommended?"
86,87,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Cetuximab', 'Encorafenib']","if a patient with metastatic colorectal adenocarcinoma cancer has braf p.v600e, what therapy is recommended?"
87,88,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Vemurafenib', 'Cobimetinib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
88,89,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Vemurafenib', 'Cobimetinib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600k, what therapy is recommended?"
89,90,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Crizotinib'],"if a patient with metastatic non-small cell lung cancer cancer has v::alk, what therapy is recommended?"
90,91,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ROS1'],['Crizotinib'],"if a patient with metastatic non-small cell lung cancer cancer has v::ros1, what therapy is recommended?"
91,92,Anaplastic Large Cell Lymphoma,anaplastic large cell lymphoma (ALCL),anaplastic large cell lymphoma,['v::ALK'],['Crizotinib'],"if a patient with anaplastic large cell lymphoma cancer has v::alk, what therapy is recommended?"
92,93,Inflammatory Myofibroblastic Tumor,"unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)","unresectable, recurrent, or refractory inflammatory myofibroblastic tumor",['v::ALK'],['Crizotinib'],"if a patient with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor cancer has v::alk, what therapy is recommended?"
93,94,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Dabrafenib'],"if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
94,95,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
95,96,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600k, what therapy is recommended?"
96,97,Melanoma,melanoma,melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with melanoma cancer has braf p.v600e, what therapy is recommended?"
97,98,Melanoma,melanoma,melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']","if a patient with melanoma cancer has braf p.v600k, what therapy is recommended?"
98,99,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Abemaciclib', 'Letrozole']","if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
99,100,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with metastatic non-small cell lung cancer cancer has braf p.v600e, what therapy is recommended?"
100,101,Anaplastic Thyroid Cancer,locally advanced or metastatic anaplastic thyroid cancer (ATC),locally advanced or metastatic anaplastic thyroid cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with locally advanced or metastatic anaplastic thyroid cancer cancer has braf p.v600e, what therapy is recommended?"
101,102,Any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with unresectable or metastatic any solid tumor cancer has braf p.v600e, what therapy is recommended?"
102,103,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with low-grade glioma, nos cancer has braf p.v600e, what therapy is recommended?"
103,104,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Dacomitinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
104,105,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Dacomitinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
105,106,Chronic Myelogenous Leukemia,philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Dasatinib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
106,107,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib'],"if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
107,108,Chronic Myelogenous Leukemia,"chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML","chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myelogenous leukemia",['BCR::ABL1'],['Dasatinib'],"if a patient with chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
108,109,"Chronic Myeloid Leukemia, BCR-ABL1+","chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML","chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib'],"if a patient with chronic, accelerated, or myeloid or lymphoid blast phase ph+ chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
109,110,Acute Lymphoid Leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL),philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Dasatinib'],"if a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, what therapy is recommended?"
110,111,Chronic Myelogenous Leukemia,philadelphia chromosome-positive CML,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Dasatinib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
111,112,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive CML,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Dasatinib'],"if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
112,113,Acute Lymphoid Leukemia,philadelphia chromosome-positive ALL,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Dasatinib'],"if a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, what therapy is recommended?"
113,114,Endometrial Carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['dMMR'],"['Carboplatin', 'Dostarlimab', 'Paclitaxel']","if a patient with primary advanced or recurrent endometrial carcinoma cancer has dmmr, what therapy is recommended?"
114,115,Endometrial Carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['MSI-H'],"['Carboplatin', 'Dostarlimab', 'Paclitaxel']","if a patient with primary advanced or recurrent endometrial carcinoma cancer has msi-h, what therapy is recommended?"
115,116,Endometrial Carcinoma,recurrent or advanced endometrial cancer,recurrent or advanced endometrial carcinoma,['dMMR'],['Dostarlimab'],"if a patient with recurrent or advanced endometrial carcinoma cancer has dmmr, what therapy is recommended?"
116,117,Any solid tumor,recurrent or advanced solid tumors,recurrent or advanced any solid tumor,['dMMR'],['Dostarlimab'],"if a patient with recurrent or advanced any solid tumor cancer has dmmr, what therapy is recommended?"
117,118,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Pemetrexed']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
118,119,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Pemetrexed', 'Cisplatin']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
119,120,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Gemcitabine']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
120,121,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Gemcitabine', 'Cisplatin']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
121,122,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Nab-paclitaxel']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
122,123,Endometrial Carcinoma,primary advanced or recurrent endometrial cancer,primary advanced or recurrent endometrial carcinoma,['dMMR'],"['Carboplatin', 'Paclitaxel', 'Durvalumab']","if a patient with primary advanced or recurrent endometrial carcinoma cancer has dmmr, what therapy is recommended?"
123,124,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['ESR1 oncogenic variants', 'HER2-negative', 'ER positive']",['Elacestrant'],"if a patient with advanced or metastatic invasive breast carcinoma cancer has esr1 oncogenic variants, her2-negative, er positive, what therapy is recommended?"
124,125,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140Q'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140q, what therapy is recommended?"
125,126,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140L'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140l, what therapy is recommended?"
126,127,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140G'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140g, what therapy is recommended?"
127,128,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R140W'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r140w, what therapy is recommended?"
128,129,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172K'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172k, what therapy is recommended?"
129,130,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172M'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172m, what therapy is recommended?"
130,131,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172G'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172g, what therapy is recommended?"
131,132,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172S'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172s, what therapy is recommended?"
132,133,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH2 p.R172W'],['Enasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh2 p.r172w, what therapy is recommended?"
133,134,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
134,135,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Binimetinib', 'Encorafenib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600k, what therapy is recommended?"
135,136,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Cetuximab', 'Encorafenib']","if a patient with metastatic colorectal adenocarcinoma cancer has braf p.v600e, what therapy is recommended?"
136,137,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Binimetinib', 'Encorafenib']","if a patient with metastatic non-small cell lung cancer cancer has braf p.v600e, what therapy is recommended?"
137,138,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ROS1'],['Entrectinib'],"if a patient with metastatic non-small cell lung cancer cancer has v::ros1, what therapy is recommended?"
138,139,Any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Entrectinib'],"if a patient with any solid tumor cancer has v::ntrk1, what therapy is recommended?"
139,140,Any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Entrectinib'],"if a patient with any solid tumor cancer has v::ntrk2, what therapy is recommended?"
140,141,Any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Entrectinib'],"if a patient with any solid tumor cancer has v::ntrk3, what therapy is recommended?"
141,142,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.R248C'],['Erdafitinib'],"if a patient with locally advanced or metastatic bladder urothelial carcinoma cancer has fgfr3 p.r248c, what therapy is recommended?"
142,143,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.S249C'],['Erdafitinib'],"if a patient with locally advanced or metastatic bladder urothelial carcinoma cancer has fgfr3 p.s249c, what therapy is recommended?"
143,144,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.G370C'],['Erdafitinib'],"if a patient with locally advanced or metastatic bladder urothelial carcinoma cancer has fgfr3 p.g370c, what therapy is recommended?"
144,145,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3 p.Y373C'],['Erdafitinib'],"if a patient with locally advanced or metastatic bladder urothelial carcinoma cancer has fgfr3 p.y373c, what therapy is recommended?"
145,146,Bladder Urothelial Carcinoma,locally advanced or metastatic urothelial carcinoma (mUC),locally advanced or metastatic bladder urothelial carcinoma,['FGFR3::TACC3'],['Erdafitinib'],"if a patient with locally advanced or metastatic bladder urothelial carcinoma cancer has fgfr3::tacc3, what therapy is recommended?"
146,147,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Erlotinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
147,148,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Erlotinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
148,149,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Exemestane', 'Everolimus']","if a patient with invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
149,150,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Exemestane', 'Everolimus']","if a patient with invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
150,151,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Exemestane', 'Everolimus']","if a patient with invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
151,152,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Fulvestrant'],"if a patient with invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
152,153,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Fulvestrant'],"if a patient with invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
153,154,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Fulvestrant'],"if a patient with invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
154,155,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,['ER positive'],['Fulvestrant'],"if a patient with invasive breast carcinoma cancer has er positive, what therapy is recommended?"
155,156,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,['PR positive'],['Fulvestrant'],"if a patient with invasive breast carcinoma cancer has pr positive, what therapy is recommended?"
156,157,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'ER positive']",['Fulvestrant'],"if a patient with invasive breast carcinoma cancer has pr positive, er positive, what therapy is recommended?"
157,158,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
158,159,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
159,160,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
160,161,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
161,162,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Palbociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
162,163,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
163,164,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
164,165,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
165,166,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Abemaciclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
166,167,Intrahepatic Cholangiocarcinoma,"unresectable, locally or metastatic intrahepatic cholangiocarcinoma","unresectable, locally or metastatic intrahepatic cholangiocarcinoma",['FGFR2::v'],['Futibatinib'],"if a patient with unresectable, locally or metastatic intrahepatic cholangiocarcinoma cancer has fgfr2::v, what therapy is recommended?"
167,168,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Gefitinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
168,169,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Gefitinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
169,170,Acute Lymphoid Leukemia,acute myeloid leukemia,acute lymphoid leukemia,['CD33 +'],['Gemtuzumab ozogamicin'],"if a patient with acute lymphoid leukemia cancer has cd33 +, what therapy is recommended?"
170,171,Acute Lymphoid Leukemia,acute myeloid leukemia,acute lymphoid leukemia,['CD33 +'],['Gemtuzumab ozogamicin'],"if a patient with acute lymphoid leukemia cancer has cd33 +, what therapy is recommended?"
171,172,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3-ITD'],['Gilteritinib'],"if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3-itd, what therapy is recommended?"
172,173,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835Y'],['Gilteritinib'],"if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835y, what therapy is recommended?"
173,174,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835A'],['Gilteritinib'],"if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835a, what therapy is recommended?"
174,175,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835E'],['Gilteritinib'],"if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835e, what therapy is recommended?"
175,176,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835H'],['Gilteritinib'],"if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835h, what therapy is recommended?"
176,177,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835N'],['Gilteritinib'],"if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835n, what therapy is recommended?"
177,178,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835S'],['Gilteritinib'],"if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835s, what therapy is recommended?"
178,179,Acute Lymphoid Leukemia,relapsed or refractory acute myeloid leukemia,relapsed or refractory acute lymphoid leukemia,['FLT3 p.D835V'],['Gilteritinib'],"if a patient with relapsed or refractory acute lymphoid leukemia cancer has flt3 p.d835v, what therapy is recommended?"
179,180,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Imatinib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
180,181,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Imatinib'],"if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
181,182,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia,philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Imatinib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
182,183,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia,"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Imatinib'],"if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
183,184,Acute Lymphoid Leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Imatinib'],"if a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, what therapy is recommended?"
184,185,Acute Lymphoid Leukemia,philadelphia chromosome-positive acute lymphoblastic leukemia,philadelphia chromosome-positive acute lymphoid leukemia,['BCR::ABL1'],['Imatinib'],"if a patient with philadelphia chromosome-positive acute lymphoid leukemia cancer has bcr::abl1, what therapy is recommended?"
185,186,Myelodysplastic Syndromes,myelodyplastic/myeloproliferative diseases (MDS/MPD),myelodysplastic syndromes,['PDGFRA rearrangements'],['Imatinib'],"if a patient with myelodysplastic syndromes cancer has pdgfra rearrangements, what therapy is recommended?"
186,187,Myelodysplastic Syndromes,myelodyplastic/myeloproliferative diseases (MDS/MPD),myelodysplastic syndromes,['PDGFRB rearrangements'],['Imatinib'],"if a patient with myelodysplastic syndromes cancer has pdgfrb rearrangements, what therapy is recommended?"
187,188,Aggressive Systemic Mastocytosis,aggressive systemic mastocytosis (ASM),aggressive systemic mastocytosis,['KIT p.D816V'],['Imatinib'],"if a patient with aggressive systemic mastocytosis cancer has kit p.d816v, what therapy is recommended?"
188,189,"Chronic Eosinophilic Leukemia, NOS",hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL),"chronic eosinophilic leukemia, nos",['FIP1L1::PDGFRA'],['Imatinib'],"if a patient with chronic eosinophilic leukemia, nos cancer has fip1l1::pdgfra, what therapy is recommended?"
189,190,Gastrointestinal Stromal Tumor,unresectable and/or metastatic maligant gastrointestinal stromal tumors (GIST),unresectable and/or metastatic maligant gastrointestinal stromal tumor,['CD117 +'],['Imatinib'],"if a patient with unresectable and/or metastatic maligant gastrointestinal stromal tumor cancer has cd117 +, what therapy is recommended?"
190,191,Gastrointestinal Stromal Tumor,GIST,gastrointestinal stromal tumor,['FIP1L1::PDGFRA'],['Imatinib'],"if a patient with gastrointestinal stromal tumor cancer has fip1l1::pdgfra, what therapy is recommended?"
191,192,Cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2::v'],['Infigratinib'],"if a patient with unresectable locally advanced or metastatic cholangiocarcinoma cancer has fgfr2::v, what therapy is recommended?"
192,193,Acute Lymphoid Leukemia,B-cell precursor acute lymphoblastic leukemia (ALL),b-cell precursor acute lymphoid leukemia,['CD22 +'],['Inotuzumab ozogamicin'],"if a patient with b-cell precursor acute lymphoid leukemia cancer has cd22 +, what therapy is recommended?"
193,194,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['MSI-H'],"['Nivolumab', 'Ipilimumab']","if a patient with metastatic colorectal adenocarcinoma cancer has msi-h, what therapy is recommended?"
194,195,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['dMMR'],"['Nivolumab', 'Ipilimumab']","if a patient with metastatic colorectal adenocarcinoma cancer has dmmr, what therapy is recommended?"
195,196,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 1%']","['Nivolumab', 'Ipilimumab']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, pd-l1 >= 1%, what therapy is recommended?"
196,197,Non-Small Cell Lung Cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Nivolumab', 'Ipilimumab', 'Pemetrexed']","if a patient with metastatic or recurrent non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
197,198,Non-Small Cell Lung Cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Cisplatin']","if a patient with metastatic or recurrent non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
198,199,Non-Small Cell Lung Cancer,metastatic or recurrent non-small cell lung cancer,metastatic or recurrent non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab', 'Ipilimumab']","if a patient with metastatic or recurrent non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
199,200,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132C'],['Ivosidenib'],"if a patient with acute myeloid leukemia cancer has idh1 p.r132c, what therapy is recommended?"
200,201,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132G'],['Ivosidenib'],"if a patient with acute myeloid leukemia cancer has idh1 p.r132g, what therapy is recommended?"
201,202,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132H'],['Ivosidenib'],"if a patient with acute myeloid leukemia cancer has idh1 p.r132h, what therapy is recommended?"
202,203,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132L'],['Ivosidenib'],"if a patient with acute myeloid leukemia cancer has idh1 p.r132l, what therapy is recommended?"
203,204,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132S'],['Ivosidenib'],"if a patient with acute myeloid leukemia cancer has idh1 p.r132s, what therapy is recommended?"
204,205,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132C'],"['Ivosidenib', 'Azacitidine']","if a patient with acute myeloid leukemia cancer has idh1 p.r132c, what therapy is recommended?"
205,206,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132G'],"['Ivosidenib', 'Azacitidine']","if a patient with acute myeloid leukemia cancer has idh1 p.r132g, what therapy is recommended?"
206,207,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132H'],"['Ivosidenib', 'Azacitidine']","if a patient with acute myeloid leukemia cancer has idh1 p.r132h, what therapy is recommended?"
207,208,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132L'],"['Ivosidenib', 'Azacitidine']","if a patient with acute myeloid leukemia cancer has idh1 p.r132l, what therapy is recommended?"
208,209,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['IDH1 p.R132S'],"['Ivosidenib', 'Azacitidine']","if a patient with acute myeloid leukemia cancer has idh1 p.r132s, what therapy is recommended?"
209,210,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132C'],['Ivosidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132c, what therapy is recommended?"
210,211,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132G'],['Ivosidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132g, what therapy is recommended?"
211,212,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132H'],['Ivosidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132h, what therapy is recommended?"
212,213,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132L'],['Ivosidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132l, what therapy is recommended?"
213,214,Acute Myeloid Leukemia,relapsed or refractory AML,relapsed or refractory acute myeloid leukemia,['IDH1 p.R132S'],['Ivosidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132s, what therapy is recommended?"
214,215,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132C'],['Ivosidenib'],"if a patient with relapsed or refractory myelodysplastic syndromes cancer has idh1 p.r132c, what therapy is recommended?"
215,216,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132G'],['Ivosidenib'],"if a patient with relapsed or refractory myelodysplastic syndromes cancer has idh1 p.r132g, what therapy is recommended?"
216,217,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132H'],['Ivosidenib'],"if a patient with relapsed or refractory myelodysplastic syndromes cancer has idh1 p.r132h, what therapy is recommended?"
217,218,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132L'],['Ivosidenib'],"if a patient with relapsed or refractory myelodysplastic syndromes cancer has idh1 p.r132l, what therapy is recommended?"
218,219,Myelodysplastic Syndromes,relapsed or refractory myelodysplastic syndromes,relapsed or refractory myelodysplastic syndromes,['IDH1 p.R132S'],['Ivosidenib'],"if a patient with relapsed or refractory myelodysplastic syndromes cancer has idh1 p.r132s, what therapy is recommended?"
219,220,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132C'],['Ivosidenib'],"if a patient with locally advanced or metastatic cholangiocarcinoma cancer has idh1 p.r132c, what therapy is recommended?"
220,221,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132G'],['Ivosidenib'],"if a patient with locally advanced or metastatic cholangiocarcinoma cancer has idh1 p.r132g, what therapy is recommended?"
221,222,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132H'],['Ivosidenib'],"if a patient with locally advanced or metastatic cholangiocarcinoma cancer has idh1 p.r132h, what therapy is recommended?"
222,223,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132L'],['Ivosidenib'],"if a patient with locally advanced or metastatic cholangiocarcinoma cancer has idh1 p.r132l, what therapy is recommended?"
223,224,Cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,locally advanced or metastatic cholangiocarcinoma,['IDH1 p.R132S'],['Ivosidenib'],"if a patient with locally advanced or metastatic cholangiocarcinoma cancer has idh1 p.r132s, what therapy is recommended?"
224,225,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,['HER2-positive'],"['Lapatinib', 'Capecitabine']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
225,226,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'ER positive']","['Lapatinib', 'Letrozole']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, er positive, what therapy is recommended?"
226,227,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'PR positive']","['Lapatinib', 'Letrozole']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, pr positive, what therapy is recommended?"
227,228,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-positive', 'PR positive', 'ER positive']","['Lapatinib', 'Letrozole']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, pr positive, er positive, what therapy is recommended?"
228,229,Any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Larotrectinib'],"if a patient with any solid tumor cancer has v::ntrk1, what therapy is recommended?"
229,230,Any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Larotrectinib'],"if a patient with any solid tumor cancer has v::ntrk2, what therapy is recommended?"
230,231,Any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Larotrectinib'],"if a patient with any solid tumor cancer has v::ntrk3, what therapy is recommended?"
231,232,Myelodysplastic Syndromes,transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS),transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes,['5q deletion'],['Lenalidomide'],"if a patient with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes cancer has 5q deletion, what therapy is recommended?"
232,233,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['v::ALK'],['Lorlatinib'],"if a patient with metastatic non-small cell lung cancer cancer has v::alk, what therapy is recommended?"
233,234,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Capecitabine']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
234,235,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Eribulin', 'Margetuximab']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
235,236,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Gemcitabine']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
236,237,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Margetuximab', 'Vinorelbine']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
237,238,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3-ITD'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3-itd, what therapy is recommended?"
238,239,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835Y'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3 p.d835y, what therapy is recommended?"
239,240,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835A'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3 p.d835a, what therapy is recommended?"
240,241,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835E'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3 p.d835e, what therapy is recommended?"
241,242,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835H'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3 p.d835h, what therapy is recommended?"
242,243,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835N'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3 p.d835n, what therapy is recommended?"
243,244,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835S'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3 p.d835s, what therapy is recommended?"
244,245,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.D835V'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3 p.d835v, what therapy is recommended?"
245,246,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['FLT3 p.I836del'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has flt3 p.i836del, what therapy is recommended?"
246,247,Acute Myeloid Leukemia,acute myeloid leukemia,acute myeloid leukemia,['CDK12 oncogenic variants'],"['Midostaurin', 'Daunorubicin', 'Cytarabine']","if a patient with acute myeloid leukemia cancer has cdk12 oncogenic variants, what therapy is recommended?"
247,248,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Mobocertinib'],"if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 20 (insertion), what therapy is recommended?"
248,249,Invasive Breast Carcinoma,early-stage breast cancer,early-stage invasive breast carcinoma,['HER2-positive'],['Neratinib'],"if a patient with early-stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
249,250,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,['HER2-positive'],"['Capecitabine', 'Neratinib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
250,251,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid (Ph+ CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
251,252,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid (Ph+ CML),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib'],"if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
252,253,Chronic Myelogenous Leukemia,chronic phase or accelerated phase Ph+ CML,chronic phase or accelerated phase ph+ chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib'],"if a patient with chronic phase or accelerated phase ph+ chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
253,254,"Chronic Myeloid Leukemia, BCR-ABL1+",chronic phase or accelerated phase Ph+ CML,"chronic phase or accelerated phase ph+ chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib'],"if a patient with chronic phase or accelerated phase ph+ chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
254,255,Ovarian Epithelial Tumor,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Niraparib'],"if a patient with recurrent ovarian epithelial tumor cancer has brca1 pathogenic variants, what therapy is recommended?"
255,256,Ovarian Epithelial Tumor,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Niraparib'],"if a patient with recurrent ovarian epithelial tumor cancer has brca2 pathogenic variants, what therapy is recommended?"
256,257,High-Grade Serous Fallopian Tube Cancer,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Niraparib'],"if a patient with recurrent high-grade serous fallopian tube cancer cancer has brca1 pathogenic variants, what therapy is recommended?"
257,258,High-Grade Serous Fallopian Tube Cancer,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Niraparib'],"if a patient with recurrent high-grade serous fallopian tube cancer cancer has brca2 pathogenic variants, what therapy is recommended?"
258,259,Peritoneal Serous Carcinoma,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Niraparib'],"if a patient with recurrent peritoneal serous carcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
259,260,Peritoneal Serous Carcinoma,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",recurrent peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Niraparib'],"if a patient with recurrent peritoneal serous carcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
260,261,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
261,262,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['PD-L1 >= 1%'],"['Nivolumab', 'Ipilimumab']","if a patient with non-small cell lung cancer cancer has pd-l1 >= 1%, what therapy is recommended?"
262,263,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Olaparib'],"if a patient with advanced ovarian epithelial tumor cancer has brca1 oncogenic variants, what therapy is recommended?"
263,264,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Olaparib'],"if a patient with advanced ovarian epithelial tumor cancer has brca1 pathogenic variants, what therapy is recommended?"
264,265,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Olaparib'],"if a patient with advanced ovarian epithelial tumor cancer has brca2 oncogenic variants, what therapy is recommended?"
265,266,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Olaparib'],"if a patient with advanced ovarian epithelial tumor cancer has brca2 pathogenic variants, what therapy is recommended?"
266,267,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Olaparib'],"if a patient with advanced high-grade serous fallopian tube cancer cancer has brca1 oncogenic variants, what therapy is recommended?"
267,268,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Olaparib'],"if a patient with advanced high-grade serous fallopian tube cancer cancer has brca1 pathogenic variants, what therapy is recommended?"
268,269,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Olaparib'],"if a patient with advanced high-grade serous fallopian tube cancer cancer has brca2 oncogenic variants, what therapy is recommended?"
269,270,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Olaparib'],"if a patient with advanced high-grade serous fallopian tube cancer cancer has brca2 pathogenic variants, what therapy is recommended?"
270,271,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Olaparib'],"if a patient with advanced peritoneal serous carcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
271,272,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Olaparib'],"if a patient with advanced peritoneal serous carcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
272,273,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Olaparib'],"if a patient with advanced peritoneal serous carcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
273,274,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Olaparib'],"if a patient with advanced peritoneal serous carcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
274,275,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced ovarian epithelial tumor cancer has brca1 oncogenic variants, what therapy is recommended?"
275,276,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced ovarian epithelial tumor cancer has brca1 pathogenic variants, what therapy is recommended?"
276,277,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced ovarian epithelial tumor cancer has brca2 oncogenic variants, what therapy is recommended?"
277,278,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced ovarian epithelial tumor cancer has brca2 pathogenic variants, what therapy is recommended?"
278,279,Ovarian Epithelial Tumor,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced ovarian epithelial tumor,['HRD'],"['Olaparib', 'Bevacizumab']","if a patient with advanced ovarian epithelial tumor cancer has hrd, what therapy is recommended?"
279,280,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced high-grade serous fallopian tube cancer cancer has brca1 oncogenic variants, what therapy is recommended?"
280,281,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced high-grade serous fallopian tube cancer cancer has brca1 pathogenic variants, what therapy is recommended?"
281,282,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced high-grade serous fallopian tube cancer cancer has brca2 oncogenic variants, what therapy is recommended?"
282,283,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced high-grade serous fallopian tube cancer cancer has brca2 pathogenic variants, what therapy is recommended?"
283,284,High-Grade Serous Fallopian Tube Cancer,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced high-grade serous fallopian tube cancer,['HRD'],"['Olaparib', 'Bevacizumab']","if a patient with advanced high-grade serous fallopian tube cancer cancer has hrd, what therapy is recommended?"
284,285,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 oncogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced peritoneal serous carcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
285,286,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA1 pathogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced peritoneal serous carcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
286,287,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 oncogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced peritoneal serous carcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
287,288,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['BRCA2 pathogenic variants'],"['Olaparib', 'Bevacizumab']","if a patient with advanced peritoneal serous carcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
288,289,Peritoneal Serous Carcinoma,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",advanced peritoneal serous carcinoma,['HRD'],"['Olaparib', 'Bevacizumab']","if a patient with advanced peritoneal serous carcinoma cancer has hrd, what therapy is recommended?"
289,290,Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Olaparib'],"if a patient with relapsed ovarian epithelial tumor cancer has brca1 oncogenic variants, what therapy is recommended?"
290,291,Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Olaparib'],"if a patient with relapsed ovarian epithelial tumor cancer has brca1 pathogenic variants, what therapy is recommended?"
291,292,Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Olaparib'],"if a patient with relapsed ovarian epithelial tumor cancer has brca2 oncogenic variants, what therapy is recommended?"
292,293,Ovarian Epithelial Tumor,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Olaparib'],"if a patient with relapsed ovarian epithelial tumor cancer has brca2 pathogenic variants, what therapy is recommended?"
293,294,High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Olaparib'],"if a patient with relapsed high-grade serous fallopian tube cancer cancer has brca1 oncogenic variants, what therapy is recommended?"
294,295,High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Olaparib'],"if a patient with relapsed high-grade serous fallopian tube cancer cancer has brca1 pathogenic variants, what therapy is recommended?"
295,296,High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Olaparib'],"if a patient with relapsed high-grade serous fallopian tube cancer cancer has brca2 oncogenic variants, what therapy is recommended?"
296,297,High-Grade Serous Fallopian Tube Cancer,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Olaparib'],"if a patient with relapsed high-grade serous fallopian tube cancer cancer has brca2 pathogenic variants, what therapy is recommended?"
297,298,Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Olaparib'],"if a patient with relapsed peritoneal serous carcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
298,299,Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Olaparib'],"if a patient with relapsed peritoneal serous carcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
299,300,Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Olaparib'],"if a patient with relapsed peritoneal serous carcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
300,301,Peritoneal Serous Carcinoma,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",relapsed peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Olaparib'],"if a patient with relapsed peritoneal serous carcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
301,302,Invasive Breast Carcinoma,high risk early breast cancer,high risk early invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Olaparib'],"if a patient with high risk early invasive breast carcinoma cancer has her2-negative, brca1 pathogenic variants, what therapy is recommended?"
302,303,Invasive Breast Carcinoma,high risk early breast cancer,high risk early invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Olaparib'],"if a patient with high risk early invasive breast carcinoma cancer has her2-negative, brca2 pathogenic variants, what therapy is recommended?"
303,304,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Olaparib'],"if a patient with metastatic invasive breast carcinoma cancer has her2-negative, brca1 pathogenic variants, what therapy is recommended?"
304,305,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Olaparib'],"if a patient with metastatic invasive breast carcinoma cancer has her2-negative, brca2 pathogenic variants, what therapy is recommended?"
305,306,Pancreatic Adenocarcinoma,metastatic pancreatic adenocarcinoma,metastatic pancreatic adenocarcinoma,['BRCA1 pathogenic variants'],['Olaparib'],"if a patient with metastatic pancreatic adenocarcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
306,307,Pancreatic Adenocarcinoma,metastatic pancreatic adenocarcinoma,metastatic pancreatic adenocarcinoma,['BRCA2 pathogenic variants'],['Olaparib'],"if a patient with metastatic pancreatic adenocarcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
307,308,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
308,309,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
309,310,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
310,311,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
311,312,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
312,313,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has atm pathogenic variants, what therapy is recommended?"
313,314,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has atm oncogenic variants, what therapy is recommended?"
314,315,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has bard1 pathogenic variants, what therapy is recommended?"
315,316,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BARD1 oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has bard1 oncogenic variants, what therapy is recommended?"
316,317,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brip1 oncogenic variants, what therapy is recommended?"
317,318,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRIP1 pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brip1 pathogenic variants, what therapy is recommended?"
318,319,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has cdk12 pathogenic variants, what therapy is recommended?"
319,320,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has cdk12 oncogenic variants, what therapy is recommended?"
320,321,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK1 pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has chek1 pathogenic variants, what therapy is recommended?"
321,322,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK1 oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has chek1 oncogenic variants, what therapy is recommended?"
322,323,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has chek2 pathogenic variants, what therapy is recommended?"
323,324,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has chek2 oncogenic variants, what therapy is recommended?"
324,325,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCL pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has fancl pathogenic variants, what therapy is recommended?"
325,326,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCL oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has fancl oncogenic variants, what therapy is recommended?"
326,327,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has palb2 pathogenic variants, what therapy is recommended?"
327,328,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has palb2 oncogenic variants, what therapy is recommended?"
328,329,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51B pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51b pathogenic variants, what therapy is recommended?"
329,330,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51B oncogenic variants'],['Talazoparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51b oncogenic variants, what therapy is recommended?"
330,331,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51c pathogenic variants, what therapy is recommended?"
331,332,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51c oncogenic variants, what therapy is recommended?"
332,333,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51D pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51d pathogenic variants, what therapy is recommended?"
333,334,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51D oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51d oncogenic variants, what therapy is recommended?"
334,335,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD54L pathogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad54l pathogenic variants, what therapy is recommended?"
335,336,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD54L oncogenic variants'],['Olaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad54l oncogenic variants, what therapy is recommended?"
336,337,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
337,338,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
338,339,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
339,340,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Prednisolone', 'Olaparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
340,341,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
341,342,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
342,343,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
343,344,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Prednisone', 'Olaparib', 'Abiraterone acetate']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
344,345,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132C'],['Olutasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132c, what therapy is recommended?"
345,346,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132G'],['Olutasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132g, what therapy is recommended?"
346,347,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132H'],['Olutasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132h, what therapy is recommended?"
347,348,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132L'],['Olutasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132l, what therapy is recommended?"
348,349,Acute Myeloid Leukemia,relapsed or refractory acute myeloid leukemia (AML),relapsed or refractory acute myeloid leukemia,['IDH1 p.R132S'],['Olutasidenib'],"if a patient with relapsed or refractory acute myeloid leukemia cancer has idh1 p.r132s, what therapy is recommended?"
349,350,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib'],"if a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
350,351,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib'],"if a patient with non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
351,352,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
352,353,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
353,354,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Osimertinib', 'Pemetrexed', 'Cisplatin']","if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
354,355,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Carboplatin', 'Osimertinib', 'Pemetrexed']","if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
355,356,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Carboplatin', 'Osimertinib', 'Pemetrexed']","if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
356,357,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Osimertinib', 'Pemetrexed', 'Cisplatin']","if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
357,358,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.T790M'],['Osimertinib'],"if a patient with metastatic non-small cell lung cancer cancer has egfr p.t790m, what therapy is recommended?"
358,359,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Palbociclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
359,360,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Palbociclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
360,361,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Palbociclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
361,362,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
362,363,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Palbociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
363,364,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Palbociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
364,365,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['Wild type KRAS', 'Wild type HRAS']","['Panitumumab', 'Oxaliplatin', 'Fluorouracil']","if a patient with metastatic colorectal adenocarcinoma cancer has wild type kras, wild type hras, what therapy is recommended?"
365,366,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,"['Wild type KRAS', 'Wild type HRAS']",['Panitumumab'],"if a patient with metastatic colorectal adenocarcinoma cancer has wild type kras, wild type hras, what therapy is recommended?"
366,367,Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Pemetrexed', 'Pembrolizumab']","if a patient with metastatic non-squamous non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
367,368,Non-Small Cell Lung Cancer,metastatic non-squamous non-small cell lung cancer,metastatic non-squamous non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Pemetrexed', 'Cisplatin', 'Pembrolizumab']","if a patient with metastatic non-squamous non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
368,369,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK', 'PD-L1 >= 1%']",['Pembrolizumab'],"if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, pd-l1 >= 1%, what therapy is recommended?"
369,370,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['PD-L1 >= 1%'],['Pembrolizumab'],"if a patient with metastatic non-small cell lung cancer cancer has pd-l1 >= 1%, what therapy is recommended?"
370,371,Head and Neck Squamous Cell Carcinoma,"metastatic or unresectable, recurrent HNSCC","metastatic or unresectable, recurrent head and neck squamous cell carcinoma",['PD-L1 (CPS) >= 1'],['Pembrolizumab'],"if a patient with metastatic or unresectable, recurrent head and neck squamous cell carcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
371,372,Any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['dMMR'],['Pembrolizumab'],"if a patient with unresectable or metastatic any solid tumor cancer has dmmr, what therapy is recommended?"
372,373,Any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['MSI-H'],['Pembrolizumab'],"if a patient with unresectable or metastatic any solid tumor cancer has msi-h, what therapy is recommended?"
373,374,Colorectal Adenocarcinoma,unresectable or metastatic ... colorectal cancer,unresectable or metastatic colorectal adenocarcinoma,['dMMR'],['Pembrolizumab'],"if a patient with unresectable or metastatic colorectal adenocarcinoma cancer has dmmr, what therapy is recommended?"
374,375,Colorectal Adenocarcinoma,unresectable or metastatic ... colorectal cancer,unresectable or metastatic colorectal adenocarcinoma,['MSI-H'],['Pembrolizumab'],"if a patient with unresectable or metastatic colorectal adenocarcinoma cancer has msi-h, what therapy is recommended?"
375,376,Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,"['HER2-positive', 'PD-L1 (CPS) >= 1']","['Trastuzumab', 'Fluorouracil', 'Cisplatin', 'Pembrolizumab']","if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction cancer has her2-positive, pd-l1 (cps) >= 1, what therapy is recommended?"
376,377,Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,"['HER2-positive', 'PD-L1 (CPS) >= 1']","['Trastuzumab', 'Oxaliplatin', 'Capecitabine', 'Pembrolizumab']","if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction cancer has her2-positive, pd-l1 (cps) >= 1, what therapy is recommended?"
377,378,Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-negative'],"['Fluorouracil', 'Cisplatin', 'Pembrolizumab']","if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction cancer has her2-negative, what therapy is recommended?"
378,379,Adenocarcinoma of the Gastroesophageal Junction,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma,locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-negative'],"['Oxaliplatin', 'Capecitabine', 'Pembrolizumab']","if a patient with locally advanced unresectable or metastatic adenocarcinoma of the gastroesophageal junction cancer has her2-negative, what therapy is recommended?"
379,380,Adenocarcinoma of the Gastroesophageal Junction,locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,locally advanced or metastatic adenocarcinoma of the gastroesophageal junction,['PD-L1 (CPS) >= 10'],['Pembrolizumab'],"if a patient with locally advanced or metastatic adenocarcinoma of the gastroesophageal junction cancer has pd-l1 (cps) >= 10, what therapy is recommended?"
380,381,Esophageal Adenocarcinoma,locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,locally advanced or metastatic esophageal adenocarcinoma,['PD-L1 (CPS) >= 10'],['Pembrolizumab'],"if a patient with locally advanced or metastatic esophageal adenocarcinoma cancer has pd-l1 (cps) >= 10, what therapy is recommended?"
381,382,Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Cisplatin', 'Pembrolizumab']","if a patient with persistent, recurrent, or metastatic cervical adenocarcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
382,383,Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Cisplatin', 'Pembrolizumab']","if a patient with persistent, recurrent, or metastatic cervical squamous cell carcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
383,384,Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Bevacizumab', 'Cisplatin', 'Pembrolizumab']","if a patient with persistent, recurrent, or metastatic cervical adenocarcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
384,385,Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Paclitaxel', 'Bevacizumab', 'Cisplatin', 'Pembrolizumab']","if a patient with persistent, recurrent, or metastatic cervical squamous cell carcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
385,386,Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']","if a patient with persistent, recurrent, or metastatic cervical adenocarcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
386,387,Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Pembrolizumab']","if a patient with persistent, recurrent, or metastatic cervical squamous cell carcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
387,388,Cervical Adenocarcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical adenocarcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Pembrolizumab']","if a patient with persistent, recurrent, or metastatic cervical adenocarcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
388,389,Cervical Squamous Cell Carcinoma,"persistent, recurrent, or metastatic cervical cancer","persistent, recurrent, or metastatic cervical squamous cell carcinoma",['PD-L1 (CPS) >= 1'],"['Carboplatin', 'Paclitaxel', 'Bevacizumab', 'Pembrolizumab']","if a patient with persistent, recurrent, or metastatic cervical squamous cell carcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
389,390,Cervical Adenocarcinoma,recurrent or metastatic cervical cancer,recurrent or metastatic cervical adenocarcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab'],"if a patient with recurrent or metastatic cervical adenocarcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
390,391,Cervical Squamous Cell Carcinoma,recurrent or metastatic cervical cancer,recurrent or metastatic cervical squamous cell carcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab'],"if a patient with recurrent or metastatic cervical squamous cell carcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
391,392,Endometrial Carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['MSI-L'],"['Lenvatinib', 'Pembrolizumab']","if a patient with advanced endometrial carcinoma cancer has msi-l, what therapy is recommended?"
392,393,Endometrial Carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['pMMR'],['Pembrolizumab'],"if a patient with advanced endometrial carcinoma cancer has pmmr, what therapy is recommended?"
393,394,Endometrial Carcinoma,advanced endometrial carcinoma,advanced endometrial carcinoma,['MSI-H'],['Pembrolizumab'],"if a patient with advanced endometrial carcinoma cancer has msi-h, what therapy is recommended?"
394,395,Any solid tumor,unresectable or metastatic ... solid tumors,unresectable or metastatic any solid tumor,['TMB-H (>= 10 mutations / Mb)'],['Pembrolizumab'],"if a patient with unresectable or metastatic any solid tumor cancer has tmb-h (>= 10 mutations / mb), what therapy is recommended?"
395,396,Invasive Breast Carcinoma,high-risk early-stage triple-negative breast cancer,high-risk early-stage triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative']","['Carboplatin', 'Doxorubicin', 'Paclitaxel', 'Cyclophosphamide', 'Pembrolizumab']","if a patient with high-risk early-stage triple-negative invasive breast carcinoma cancer has er negative, pr negative, her2-negative, what therapy is recommended?"
396,397,Invasive Breast Carcinoma,locally recurrent unresectable or metastatic triple-negative breast cancer,locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative', 'PD-L1 (CPS) >= 10']","['Paclitaxel', 'Pembrolizumab']","if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma cancer has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, what therapy is recommended?"
397,398,Invasive Breast Carcinoma,locally recurrent unresectable or metastatic triple-negative breast cancer,locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative', 'PD-L1 (CPS) >= 10']","['Carboplatin', 'Gemcitabine', 'Pembrolizumab']","if a patient with locally recurrent unresectable or metastatic triple-negative invasive breast carcinoma cancer has er negative, pr negative, her2-negative, pd-l1 (cps) >= 10, what therapy is recommended?"
398,399,Cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2::v'],['Pemigatinib'],"if a patient with unresectable locally advanced or metastatic cholangiocarcinoma cancer has fgfr2::v, what therapy is recommended?"
399,400,Cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,unresectable locally advanced or metastatic cholangiocarcinoma,['FGFR2 rearrangements'],['Pemigatinib'],"if a patient with unresectable locally advanced or metastatic cholangiocarcinoma cancer has fgfr2 rearrangements, what therapy is recommended?"
400,401,Myeloid/Lymphoid Neoplasms,relapsed or refractory myeloid/lymphoid neoplasms (MLNs),relapsed or refractory myeloid/lymphoid neoplasms,['FGFR1 rearrangements'],['Pemigatinib'],"if a patient with relapsed or refractory myeloid/lymphoid neoplasms cancer has fgfr1 rearrangements, what therapy is recommended?"
401,402,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
402,403,Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with locally advanced, inflammatory, or early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
403,404,Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with locally advanced, inflammatory, or early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
404,405,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab']","if a patient with metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
405,406,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
406,407,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
407,408,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
408,409,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
409,410,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
410,411,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
411,412,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
412,413,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Carboplatin', 'Docetaxel', 'Pertuzumab']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
413,414,Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with locally advanced, inflammatory, or early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
414,415,Invasive Breast Carcinoma,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)","locally advanced, inflammatory, or early stage invasive breast carcinoma",['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with locally advanced, inflammatory, or early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
415,416,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Carboplatin', 'Docetaxel', 'Pertuzumab']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
416,417,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
417,418,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
418,419,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Fluorouracil', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
419,420,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
420,421,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Paclitaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
421,422,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Docetaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
422,423,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with early invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
423,424,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Doxorubicin', 'Paclitaxel', 'Pertuzumab', 'Cyclophosphamide']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
424,425,Invasive Breast Carcinoma,early stage breast cancer,early stage invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Fluorouracil', 'Docetaxel', 'Pertuzumab', 'Epirubicin', 'Cyclophosphamide']","if a patient with early stage invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
425,426,Acute Lymphoid Leukemia,Ph+ ALL,acute lymphoid leukemia,['BCR::ABL1'],"['Prednisone', 'Ponatinib', 'Vincristine', 'Methotrexate', 'Cytarabine']","if a patient with acute lymphoid leukemia cancer has bcr::abl1, what therapy is recommended?"
426,427,Acute Lymphoid Leukemia,Ph+ ALL,acute lymphoid leukemia,"['ABL1 p.T315I', 'BCR::ABL1']",['Ponatinib'],"if a patient with acute lymphoid leukemia cancer has abl1 p.t315i, bcr::abl1, what therapy is recommended?"
427,428,Chronic Myelogenous Leukemia,CML,chronic myelogenous leukemia,['ABL1 p.T315I'],['Ponatinib'],"if a patient with chronic myelogenous leukemia cancer has abl1 p.t315i, what therapy is recommended?"
428,429,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::RET'],['Pralsetinib'],"if a patient with non-small cell lung cancer cancer has v::ret, what therapy is recommended?"
429,430,Papillary Thyroid Cancer,advanced or metastatic... thyroid cancer,advanced or metastatic papillary thyroid cancer,['v::RET'],['Pralsetinib'],"if a patient with advanced or metastatic papillary thyroid cancer cancer has v::ret, what therapy is recommended?"
430,431,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Erlotinib', 'Ramucirumab']","if a patient with metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
431,432,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Erlotinib', 'Ramucirumab']","if a patient with metastatic non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
432,433,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['v::ROS1'],['Repotrectinib'],"if a patient with locally advanced or metastatic non-small cell lung cancer cancer has v::ros1, what therapy is recommended?"
433,434,Any solid tumor,solid tumors,any solid tumor,['v::NTRK1'],['Repotrectinib'],"if a patient with any solid tumor cancer has v::ntrk1, what therapy is recommended?"
434,435,Any solid tumor,solid tumors,any solid tumor,['v::NTRK2'],['Repotrectinib'],"if a patient with any solid tumor cancer has v::ntrk2, what therapy is recommended?"
435,436,Any solid tumor,solid tumors,any solid tumor,['v::NTRK3'],['Repotrectinib'],"if a patient with any solid tumor cancer has v::ntrk3, what therapy is recommended?"
436,437,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
437,438,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
438,439,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
439,440,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Ribociclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
440,441,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Ribociclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
441,442,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Ribociclib', 'Letrozole']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
442,443,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
443,444,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Fulvestrant', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
444,445,Invasive Breast Carcinoma,advanced or metastatic breast cancer,advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Fulvestrant', 'Ribociclib']","if a patient with advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
445,446,Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),b-cell non-hodgkin lymphoma,['CD20 +'],['Rituximab'],"if a patient with b-cell non-hodgkin lymphoma cancer has cd20 +, what therapy is recommended?"
446,447,Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),b-cell non-hodgkin lymphoma,['CD20 +'],"['Prednisolone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']","if a patient with b-cell non-hodgkin lymphoma cancer has cd20 +, what therapy is recommended?"
447,448,Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),b-cell non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisolone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']","if a patient with b-cell non-hodgkin lymphoma cancer has cd20 +, what therapy is recommended?"
448,449,Non-Hodgkin Lymphoma,B-cell Non-Hodgkin's Lymphoma (NHL),b-cell non-hodgkin lymphoma,['CD20 +'],"['Rituximab', 'Mitoxantrone', 'Fludarabine', 'Cyclophosphamide']","if a patient with b-cell non-hodgkin lymphoma cancer has cd20 +, what therapy is recommended?"
449,451,Non-Hodgkin Lymphoma,Non-Hodgkin's Lymphoma (NHL),non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']","if a patient with non-hodgkin lymphoma cancer has cd20 +, what therapy is recommended?"
450,452,Non-Hodgkin Lymphoma,diffuse large B-cell Non-Hodgkin's Lymhpoma (NHL),diffuse large b-cell non-hodgkin lymphoma,['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']","if a patient with diffuse large b-cell non-hodgkin lymphoma cancer has cd20 +, what therapy is recommended?"
451,453,Diffuse Large B-Cell Lymphoma,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)","previously untreated, advanced stage, cd20-positive diffuse large b-cell lymphoma",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']","if a patient with previously untreated, advanced stage, cd20-positive diffuse large b-cell lymphoma cancer has cd20 +, what therapy is recommended?"
452,454,Burkitt Lymphoma,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)","previously untreated, advanced stage, cd20-positive burkitt lymphoma",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']","if a patient with previously untreated, advanced stage, cd20-positive burkitt lymphoma cancer has cd20 +, what therapy is recommended?"
453,455,Mature B-Cell Neoplasms,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)","previously untreated, advanced stage, cd20-positive mature b-cell neoplasms",['CD20 +'],"['Doxorubicin', 'Prednisone', 'Vincristine', 'Rituximab', 'Cyclophosphamide']","if a patient with previously untreated, advanced stage, cd20-positive mature b-cell neoplasms cancer has cd20 +, what therapy is recommended?"
454,456,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leuekmia (CLL),chronic lymphocytic leukemia,['CD20 +'],"['Rituximab', 'Fludarabine', 'Cyclophosphamide']","if a patient with chronic lymphocytic leukemia cancer has cd20 +, what therapy is recommended?"
455,457,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA1 oncogenic variants'],['Rucaparib'],"if a patient with ovarian epithelial tumor cancer has brca1 oncogenic variants, what therapy is recommended?"
456,458,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA1 pathogenic variants'],['Rucaparib'],"if a patient with ovarian epithelial tumor cancer has brca1 pathogenic variants, what therapy is recommended?"
457,459,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA2 oncogenic variants'],['Rucaparib'],"if a patient with ovarian epithelial tumor cancer has brca2 oncogenic variants, what therapy is recommended?"
458,460,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",ovarian epithelial tumor,['BRCA2 pathogenic variants'],['Rucaparib'],"if a patient with ovarian epithelial tumor cancer has brca2 pathogenic variants, what therapy is recommended?"
459,461,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA1 oncogenic variants'],['Rucaparib'],"if a patient with high-grade serous fallopian tube cancer cancer has brca1 oncogenic variants, what therapy is recommended?"
460,462,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA1 pathogenic variants'],['Rucaparib'],"if a patient with high-grade serous fallopian tube cancer cancer has brca1 pathogenic variants, what therapy is recommended?"
461,463,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA2 oncogenic variants'],['Rucaparib'],"if a patient with high-grade serous fallopian tube cancer cancer has brca2 oncogenic variants, what therapy is recommended?"
462,464,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",high-grade serous fallopian tube cancer,['BRCA2 pathogenic variants'],['Rucaparib'],"if a patient with high-grade serous fallopian tube cancer cancer has brca2 pathogenic variants, what therapy is recommended?"
463,465,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA1 oncogenic variants'],['Rucaparib'],"if a patient with peritoneal serous carcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
464,466,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA1 pathogenic variants'],['Rucaparib'],"if a patient with peritoneal serous carcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
465,467,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA2 oncogenic variants'],['Rucaparib'],"if a patient with peritoneal serous carcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
466,468,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal cancer",peritoneal serous carcinoma,['BRCA2 pathogenic variants'],['Rucaparib'],"if a patient with peritoneal serous carcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
467,469,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 oncogenic variants'],['Rucaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 oncogenic variants, what therapy is recommended?"
468,470,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],['Rucaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
469,471,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],['Rucaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
470,472,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],['Rucaparib'],"if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
471,473,Invasive Breast Carcinoma,unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC),unresectable locally advanced or metastatic triple-negative invasive breast carcinoma,"['ER negative', 'PR negative', 'HER2-negative']",['Sacituzumab govitecan'],"if a patient with unresectable locally advanced or metastatic triple-negative invasive breast carcinoma cancer has er negative, pr negative, her2-negative, what therapy is recommended?"
472,474,Invasive Breast Carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Sacituzumab govitecan'],"if a patient with locally advanced or metastatic invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
473,475,Invasive Breast Carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative']",['Sacituzumab govitecan'],"if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
474,476,Invasive Breast Carcinoma,locally advanced or metastatic ... breast cancer,locally advanced or metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Sacituzumab govitecan'],"if a patient with locally advanced or metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
475,477,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['v::RET'],['Selpercatinib'],"if a patient with locally advanced or metastatic non-small cell lung cancer cancer has v::ret, what therapy is recommended?"
476,478,Medullary Thyroid Cancer,advanced or metastatic medullary thyroid cancer,advanced or metastatic medullary thyroid cancer,['RET oncogenic variants'],['Selpercatinib'],"if a patient with advanced or metastatic medullary thyroid cancer cancer has ret oncogenic variants, what therapy is recommended?"
477,479,Anaplastic Thyroid Cancer,advanced or metastatic thyroid cancer,advanced or metastatic anaplastic thyroid cancer,['v::RET'],['Selpercatinib'],"if a patient with advanced or metastatic anaplastic thyroid cancer cancer has v::ret, what therapy is recommended?"
478,480,Any solid tumor,locally advanced or metastatic solid tumors,locally advanced or metastatic any solid tumor,['v::RET'],['Selpercatinib'],"if a patient with locally advanced or metastatic any solid tumor cancer has v::ret, what therapy is recommended?"
479,481,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['KRAS p.G12C'],['Sotorasib'],"if a patient with locally advanced or metastatic non-small cell lung cancer cancer has kras p.g12c, what therapy is recommended?"
480,482,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA1 pathogenic variants']",['Talazoparib'],"if a patient with locally advanced or metastatic invasive breast carcinoma cancer has her2-negative, brca1 pathogenic variants, what therapy is recommended?"
481,483,Invasive Breast Carcinoma,locally advanced or metastatic breast cancer,locally advanced or metastatic invasive breast carcinoma,"['HER2-negative', 'BRCA2 pathogenic variants']",['Talazoparib'],"if a patient with locally advanced or metastatic invasive breast carcinoma cancer has her2-negative, brca2 pathogenic variants, what therapy is recommended?"
482,484,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['MET Exon 14 (Splice Site)'],['Tepotinib'],"if a patient with non-small cell lung cancer cancer has met exon 14 (splice site), what therapy is recommended?"
483,485,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['MET Exon 14 (Deletion)'],['Tepotinib'],"if a patient with non-small cell lung cancer cancer has met exon 14 (deletion), what therapy is recommended?"
484,486,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Trametinib'],"if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
485,487,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],['Trametinib'],"if a patient with unresectable or metastatic melanoma cancer has braf p.v600k, what therapy is recommended?"
486,488,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
487,489,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600K'],"['Trametinib', 'Dabrafenib']","if a patient with unresectable or metastatic melanoma cancer has braf p.v600k, what therapy is recommended?"
488,490,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with metastatic non-small cell lung cancer cancer has braf p.v600e, what therapy is recommended?"
489,491,Anaplastic Thyroid Cancer,locally advanced or metastatic anaplastic thyroid cancer,locally advanced or metastatic anaplastic thyroid cancer,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with locally advanced or metastatic anaplastic thyroid cancer cancer has braf p.v600e, what therapy is recommended?"
490,492,Any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with unresectable or metastatic any solid tumor cancer has braf p.v600e, what therapy is recommended?"
491,493,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF p.V600E'],"['Trametinib', 'Dabrafenib']","if a patient with low-grade glioma, nos cancer has braf p.v600e, what therapy is recommended?"
492,494,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,['HER2-positive'],['Trastuzumab'],"if a patient with invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
493,495,Gastrointestinal Stromal Tumor,metastatic gastric or gastroesophageal junction adenocarcinoma,metastatic gastrointestinal stromal tumor,['HER2-positive'],['Trastuzumab'],"if a patient with metastatic gastrointestinal stromal tumor cancer has her2-positive, what therapy is recommended?"
494,496,Invasive Breast Carcinoma,unresectable or metastatic breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-positive'],['Trastuzumab deruxtecan'],"if a patient with unresectable or metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
495,497,Invasive Breast Carcinoma,unresectable or metastatic ... breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-low'],['Trastuzumab deruxtecan'],"if a patient with unresectable or metastatic invasive breast carcinoma cancer has her2-low, what therapy is recommended?"
496,498,Non-Small Cell Lung Cancer,unresectable or metastatic non-small cell lung cancer,unresectable or metastatic non-small cell lung cancer,['ERBB2 oncogenic variants'],['Trastuzumab deruxtecan'],"if a patient with unresectable or metastatic non-small cell lung cancer cancer has erbb2 oncogenic variants, what therapy is recommended?"
497,499,Adenocarcinoma of the Gastroesophageal Junction,locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma,locally advanced or metastatic adenocarcinoma of the gastroesophageal junction,['HER2-positive'],['Trastuzumab deruxtecan'],"if a patient with locally advanced or metastatic adenocarcinoma of the gastroesophageal junction cancer has her2-positive, what therapy is recommended?"
498,500,Any solid tumor,unresectable or metastatic solid tumors,unresectable or metastatic any solid tumor,['HER2-positive'],['Trastuzumab deruxtecan'],"if a patient with unresectable or metastatic any solid tumor cancer has her2-positive, what therapy is recommended?"
499,501,Invasive Breast Carcinoma,advanced unresectable or metastatic breast cancer,unresectable or metastatic invasive breast carcinoma,['HER2-positive'],"['Trastuzumab', 'Capecitabine', 'Tucatinib']","if a patient with unresectable or metastatic invasive breast carcinoma cancer has her2-positive, what therapy is recommended?"
500,502,Melanoma,unresectable or metastatic melanoma,unresectable or metastatic melanoma,['BRAF p.V600E'],['Vemurafenib'],"if a patient with unresectable or metastatic melanoma cancer has braf p.v600e, what therapy is recommended?"
501,503,Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,Erdheim-Chester Disease,non-langerhans cell histiocytosis/erdheim-chester disease,['BRAF p.V600E'],['Vemurafenib'],"if a patient with non-langerhans cell histiocytosis/erdheim-chester disease cancer has braf p.v600e, what therapy is recommended?"
502,504,Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,Erdheim-Chester Disease,non-langerhans cell histiocytosis/erdheim-chester disease,['BRAF p.V600K'],['Vemurafenib'],"if a patient with non-langerhans cell histiocytosis/erdheim-chester disease cancer has braf p.v600k, what therapy is recommended?"
503,505,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646N'],['Tazemetostat'],"if a patient with follicular lymphoma cancer has ezh2 p.y646n, what therapy is recommended?"
504,506,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646F'],['Tazemetostat'],"if a patient with follicular lymphoma cancer has ezh2 p.y646f, what therapy is recommended?"
505,507,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646H'],['Tazemetostat'],"if a patient with follicular lymphoma cancer has ezh2 p.y646h, what therapy is recommended?"
506,508,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646S'],['Tazemetostat'],"if a patient with follicular lymphoma cancer has ezh2 p.y646s, what therapy is recommended?"
507,509,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.Y646C'],['Tazemetostat'],"if a patient with follicular lymphoma cancer has ezh2 p.y646c, what therapy is recommended?"
508,510,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.A862G'],['Tazemetostat'],"if a patient with follicular lymphoma cancer has ezh2 p.a862g, what therapy is recommended?"
509,511,Follicular Lymphoma,follicular lymphoma,follicular lymphoma,['EZH2 p.A692V'],['Tazemetostat'],"if a patient with follicular lymphoma cancer has ezh2 p.a692v, what therapy is recommended?"
510,512,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA1 pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca1 pathogenic variants, what therapy is recommended?"
511,513,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 oncogenic variants, what therapy is recommended?"
512,514,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['BRCA2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has brca2 pathogenic variants, what therapy is recommended?"
513,515,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has atm pathogenic variants, what therapy is recommended?"
514,516,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATM oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has atm oncogenic variants, what therapy is recommended?"
515,517,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATR oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has atr oncogenic variants, what therapy is recommended?"
516,518,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has cdk12 oncogenic variants, what therapy is recommended?"
517,519,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['ATR pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has atr pathogenic variants, what therapy is recommended?"
518,520,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCA oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has fanca oncogenic variants, what therapy is recommended?"
519,521,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has chek2 pathogenic variants, what therapy is recommended?"
520,522,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CHEK2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has chek2 oncogenic variants, what therapy is recommended?"
521,523,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['FANCA pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has fanca pathogenic variants, what therapy is recommended?"
522,524,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MLH1 oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has mlh1 oncogenic variants, what therapy is recommended?"
523,525,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has palb2 pathogenic variants, what therapy is recommended?"
524,526,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['PALB2 oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has palb2 oncogenic variants, what therapy is recommended?"
525,527,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MLH1 pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has mlh1 pathogenic variants, what therapy is recommended?"
526,528,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MRE11 oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has mre11 oncogenic variants, what therapy is recommended?"
527,529,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51c pathogenic variants, what therapy is recommended?"
528,530,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['RAD51C oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has rad51c oncogenic variants, what therapy is recommended?"
529,531,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['MRE11 pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has mre11 pathogenic variants, what therapy is recommended?"
530,532,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['NBN oncogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has nbn oncogenic variants, what therapy is recommended?"
531,533,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['NBN pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has nbn pathogenic variants, what therapy is recommended?"
532,534,Renal Angiomyolipoma,renal angiomyolipoma,renal angiomyolipoma,['TSC1 oncogenic variants'],['Everolimus'],"if a patient with renal angiomyolipoma cancer has tsc1 oncogenic variants, what therapy is recommended?"
533,535,Renal Angiomyolipoma,renal angiomyolipoma,renal angiomyolipoma,['TSC2 oncogenic variants'],['Everolimus'],"if a patient with renal angiomyolipoma cancer has tsc2 oncogenic variants, what therapy is recommended?"
534,536,Anaplastic Thyroid Cancer,subependymal giant cell astrocytoma,anaplastic thyroid cancer,['TSC1 oncogenic variants'],['Everolimus'],"if a patient with anaplastic thyroid cancer cancer has tsc1 oncogenic variants, what therapy is recommended?"
535,537,Anaplastic Thyroid Cancer,subependymal giant cell astrocytoma,anaplastic thyroid cancer,['TSC2 oncogenic variants'],['Everolimus'],"if a patient with anaplastic thyroid cancer cancer has tsc2 oncogenic variants, what therapy is recommended?"
536,538,Prostate Adenocarcinoma,metastatic castration-resistant prostate cancer,metastatic castration-resistant prostate adenocarcinoma,['CDK12 pathogenic variants'],"['Enzalutamide', 'Talazoparib']","if a patient with metastatic castration-resistant prostate adenocarcinoma cancer has cdk12 pathogenic variants, what therapy is recommended?"
537,539,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Osimertinib'],"if a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
538,540,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Osimertinib'],"if a patient with non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
539,541,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Amivantamab', 'Lazertinib']","if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
540,542,Non-Small Cell Lung Cancer,locally advanced or metastatic non-small cell lung cancer,locally advanced or metastatic non-small cell lung cancer,['EGFR p.L858R'],"['Amivantamab', 'Lazertinib']","if a patient with locally advanced or metastatic non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
541,543,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Amivantamab', 'Lazertinib']","if a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
542,544,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],"['Amivantamab', 'Lazertinib']","if a patient with non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
543,545,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']","if a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
544,546,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],"['Carboplatin', 'Amivantamab', 'Pemetrexed']","if a patient with non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
545,547,Ovarian Epithelial Tumor,"epithelial ovarian, fallopian tube, or primary peritoneal",ovarian epithelial tumor,['FOLR1 positive'],['Mirvetuximab soravtansine'],"if a patient with ovarian epithelial tumor cancer has folr1 positive, what therapy is recommended?"
546,548,High-Grade Serous Fallopian Tube Cancer,"epithelial ovarian, fallopian tube, or primary peritoneal",high-grade serous fallopian tube cancer,['FOLR1 positive'],['Mirvetuximab soravtansine'],"if a patient with high-grade serous fallopian tube cancer cancer has folr1 positive, what therapy is recommended?"
547,549,Peritoneal Serous Carcinoma,"epithelial ovarian, fallopian tube, or primary peritoneal",peritoneal serous carcinoma,['FOLR1 positive'],['Mirvetuximab soravtansine'],"if a patient with peritoneal serous carcinoma cancer has folr1 positive, what therapy is recommended?"
548,550,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF rearrangements'],['Tovorafenib'],"if a patient with low-grade glioma, nos cancer has braf rearrangements, what therapy is recommended?"
549,551,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['v::BRAF'],['Tovorafenib'],"if a patient with low-grade glioma, nos cancer has v::braf, what therapy is recommended?"
550,552,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF p.V600E'],['Tovorafenib'],"if a patient with low-grade glioma, nos cancer has braf p.v600e, what therapy is recommended?"
551,553,"Low-Grade Glioma, NOS",low-grade glioma (LGG),"low-grade glioma, nos",['BRAF p.V600K'],['Tovorafenib'],"if a patient with low-grade glioma, nos cancer has braf p.v600k, what therapy is recommended?"
552,554,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Durvalumab']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
553,555,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Durvalumab', 'Gemcitabine', 'Cisplatin']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
554,556,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Durvalumab', 'Pemetrexed', 'Cisplatin']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
555,557,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Durvalumab', 'Pemetrexed']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
556,558,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['KRAS p.G12C'],"['Adagrasib', 'Cetuximab']","if a patient with colorectal adenocarcinoma cancer has kras p.g12c, what therapy is recommended?"
557,559,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132C'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh1 p.r132c, what therapy is recommended?"
558,560,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132G'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh1 p.r132g, what therapy is recommended?"
559,561,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132H'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh1 p.r132h, what therapy is recommended?"
560,562,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132L'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh1 p.r132l, what therapy is recommended?"
561,563,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH1 p.R132S'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh1 p.r132s, what therapy is recommended?"
562,564,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172K'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh2 p.r172k, what therapy is recommended?"
563,565,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172M'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh2 p.r172m, what therapy is recommended?"
564,566,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172G'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh2 p.r172g, what therapy is recommended?"
565,567,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172S'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh2 p.r172s, what therapy is recommended?"
566,568,Astrocytoma,astrocytoma or oligodendroglioma,astrocytoma,['IDH2 p.R172W'],['Vorasidenib'],"if a patient with astrocytoma cancer has idh2 p.r172w, what therapy is recommended?"
567,569,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132C'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh1 p.r132c, what therapy is recommended?"
568,570,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132G'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh1 p.r132g, what therapy is recommended?"
569,571,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132H'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh1 p.r132h, what therapy is recommended?"
570,572,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132L'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh1 p.r132l, what therapy is recommended?"
571,573,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH1 p.R132S'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh1 p.r132s, what therapy is recommended?"
572,574,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172K'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh2 p.r172k, what therapy is recommended?"
573,575,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172M'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh2 p.r172m, what therapy is recommended?"
574,576,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172G'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh2 p.r172g, what therapy is recommended?"
575,577,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172S'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh2 p.r172s, what therapy is recommended?"
576,578,Oligodendroglioma,astrocytoma or oligodendroglioma,oligodendroglioma,['IDH2 p.R172W'],['Vorasidenib'],"if a patient with oligodendroglioma cancer has idh2 p.r172w, what therapy is recommended?"
577,579,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Goserelin', 'Anastrozole', 'Ribociclib']","if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
578,580,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Goserelin', 'Anastrozole', 'Ribociclib']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
579,581,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Goserelin', 'Anastrozole', 'Ribociclib']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
580,582,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Goserelin', 'Ribociclib', 'Letrozole']","if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
581,583,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Goserelin', 'Ribociclib', 'Letrozole']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
582,584,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Goserelin', 'Ribociclib', 'Letrozole']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
583,585,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Pemetrexed', 'Cisplatin']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
584,586,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Gemcitabine', 'Cisplatin']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
585,587,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Nivolumab', 'Ipilimumab', 'Pemetrexed']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
586,588,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Nivolumab', 'Ipilimumab', 'Pemetrexed', 'Cisplatin']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
587,589,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Carboplatin', 'Paclitaxel', 'Nivolumab', 'Ipilimumab']","if a patient with non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
588,591,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['dMMR'],"['Nivolumab', 'Ipilimumab']","if a patient with colorectal adenocarcinoma cancer has dmmr, what therapy is recommended?"
589,592,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['MSI-H'],['Nivolumab'],"if a patient with colorectal adenocarcinoma cancer has msi-h, what therapy is recommended?"
590,593,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['dMMR'],['Nivolumab'],"if a patient with colorectal adenocarcinoma cancer has dmmr, what therapy is recommended?"
591,594,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']","if a patient with metastatic invasive breast carcinoma cancer has her2-negative, er positive, pik3ca somatic variants, what therapy is recommended?"
592,595,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']","if a patient with metastatic invasive breast carcinoma cancer has pr positive, her2-negative, pik3ca somatic variants, what therapy is recommended?"
593,596,Invasive Breast Carcinoma,metastatic breast cancer,metastatic invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive', 'PIK3CA somatic variants']","['Inavolisib', 'Fulvestrant', 'Palbociclib']","if a patient with metastatic invasive breast carcinoma cancer has pr positive, her2-negative, er positive, pik3ca somatic variants, what therapy is recommended?"
594,597,Adenocarcinoma of the Gastroesophageal Junction,gastric or gastroesophageal junction adenocarcinoma,adenocarcinoma of the gastroesophageal junction,"['HER2-negative', 'CLDN18.2 >= 75%']","['Oxaliplatin', 'Fluorouracil', 'Zolbetuximab']","if a patient with adenocarcinoma of the gastroesophageal junction cancer has her2-negative, cldn18.2 >= 75%, what therapy is recommended?"
595,598,Adenocarcinoma of the Gastroesophageal Junction,gastric or gastroesophageal junction adenocarcinoma,adenocarcinoma of the gastroesophageal junction,"['HER2-negative', 'CLDN18.2 >= 75%']","['Oxaliplatin', 'Zolbetuximab', 'Capecitabine']","if a patient with adenocarcinoma of the gastroesophageal junction cancer has her2-negative, cldn18.2 >= 75%, what therapy is recommended?"
596,599,Intraductal Papillary Neoplasm of the Bile Duct,biliary tract cancer (BTC),intraductal papillary neoplasm of the bile duct,['HER2-positive'],['Zanidatamab'],"if a patient with intraductal papillary neoplasm of the bile duct cancer has her2-positive, what therapy is recommended?"
597,600,Intracholecystic Papillary Neoplasm,biliary tract cancer (BTC),intracholecystic papillary neoplasm,['HER2-positive'],['Zanidatamab'],"if a patient with intracholecystic papillary neoplasm cancer has her2-positive, what therapy is recommended?"
598,601,Cholangiocarcinoma,biliary tract cancer (BTC),cholangiocarcinoma,['HER2-positive'],['Zanidatamab'],"if a patient with cholangiocarcinoma cancer has her2-positive, what therapy is recommended?"
599,602,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::NRG1'],['Zenocutuzumab'],"if a patient with non-small cell lung cancer cancer has v::nrg1, what therapy is recommended?"
600,603,Pancreatic Adenocarcinoma,pancreatic adenocarcinoma,pancreatic adenocarcinoma,['v::NRG1'],['Zenocutuzumab'],"if a patient with pancreatic adenocarcinoma cancer has v::nrg1, what therapy is recommended?"
601,604,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ALK'],['Ensartinib'],"if a patient with non-small cell lung cancer cancer has v::alk, what therapy is recommended?"
602,605,Colorectal Adenocarcinoma,metastatic colorectal cancer,metastatic colorectal adenocarcinoma,['BRAF p.V600E'],"['Oxaliplatin', 'Fluorouracil', 'Cetuximab', 'Encorafenib']","if a patient with metastatic colorectal adenocarcinoma cancer has braf p.v600e, what therapy is recommended?"
603,606,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Asciminib'],"if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
604,607,"Chronic Myeloid Leukemia, BCR-ABL1+",philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),"philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Asciminib'],"if a patient with philadelphia chromosome-positive chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
605,608,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Pemetrexed']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
606,609,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Pemetrexed', 'Cisplatin']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
607,610,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Gemcitabine']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
608,611,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Durvalumab', 'Gemcitabine', 'Cisplatin']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
609,612,Non-Small Cell Lung Cancer,metastatic non-small cell lung cancer,metastatic non-small cell lung cancer,"['Wild type EGFR', 'Wild type ALK']","['Tremelimumab', 'Carboplatin', 'Durvalumab', 'Nab-paclitaxel']","if a patient with metastatic non-small cell lung cancer cancer has wild type egfr, wild type alk, what therapy is recommended?"
610,613,Acute Lymphoid Leukemia,acute leukemia,acute lymphoid leukemia,['t(KMT2A;v)'],['Revumenib'],"if a patient with acute lymphoid leukemia cancer has t(kmt2a;v), what therapy is recommended?"
611,614,Acute Myeloid Leukemia,acute leukemia,acute myeloid leukemia,['t(KMT2A;v)'],['Revumenib'],"if a patient with acute myeloid leukemia cancer has t(kmt2a;v), what therapy is recommended?"
612,615,Burkitt Lymphoma,acute leukemia,burkitt lymphoma,['t(KMT2A;v)'],['Revumenib'],"if a patient with burkitt lymphoma cancer has t(kmt2a;v), what therapy is recommended?"
613,616,Acute Leukemias of Ambiguous Lineage,acute leukemia,acute leukemias of ambiguous lineage,['t(KMT2A;v)'],['Revumenib'],"if a patient with acute leukemias of ambiguous lineage cancer has t(kmt2a;v), what therapy is recommended?"
614,617,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Abemaciclib', 'Letrozole']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
615,618,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
616,619,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Anastrozole', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
617,620,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Anastrozole', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
618,621,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']","['Exemestane', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
619,622,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['HER2-negative', 'ER positive']","['Exemestane', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
620,623,Invasive Breast Carcinoma,early breast cancer,early invasive breast carcinoma,"['PR positive', 'HER2-negative']","['Exemestane', 'Abemaciclib']","if a patient with early invasive breast carcinoma cancer has pr positive, her2-negative, what therapy is recommended?"
621,624,Colorectal Adenocarcinoma,colorectal cancer,colorectal adenocarcinoma,['MSI-H'],"['Nivolumab', 'Ipilimumab']","if a patient with colorectal adenocarcinoma cancer has msi-h, what therapy is recommended?"
622,625,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['v::ROS1'],['Taletrectinib'],"if a patient with non-small cell lung cancer cancer has v::ros1, what therapy is recommended?"
623,626,Lung Non-Squamous Non-Small Cell Carcinoma,non-squamous non-small cell lung cancer,lung non-squamous non-small cell carcinoma,['c-Met >= 50%'],['Telisotuzumab Vedotin'],"if a patient with lung non-squamous non-small cell carcinoma cancer has c-met >= 50%, what therapy is recommended?"
624,627,Low-Grade Serous Ovarian Cancer,low-grade serous ovarian cancer (LGSOC),low-grade serous ovarian cancer,['KRAS p.G12C'],"['Avutometinib', 'Defactinib']","if a patient with low-grade serous ovarian cancer cancer has kras p.g12c, what therapy is recommended?"
625,628,Low-Grade Serous Ovarian Cancer,low-grade serous ovarian cancer (LGSOC),low-grade serous ovarian cancer,['KRAS p.G12V'],"['Avutometinib', 'Defactinib']","if a patient with low-grade serous ovarian cancer cancer has kras p.g12v, what therapy is recommended?"
626,629,APL with PML-RARA,low-risk acute promyelocytic leukemia (APL),low-risk apl with pml-rara,['t(15;17)'],['Arsenic trioxide'],"if a patient with low-risk apl with pml-rara cancer has t(15;17), what therapy is recommended?"
627,630,APL with PML-RARA,acute promyelocytic leukemia (APL),apl with pml-rara,['t(15;17)'],['Arsenic trioxide'],"if a patient with apl with pml-rara cancer has t(15;17), what therapy is recommended?"
628,631,Chronic Myelogenous Leukemia,Ph+ CML-CP and CML-AP,chronic myelogenous leukemia,['BCR::ABL1'],['Nilotinib'],"if a patient with chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
629,632,"Chronic Myeloid Leukemia, BCR-ABL1+",Ph+ CML-CP and CML-AP,"chronic myeloid leukemia, bcr-abl1+",['BCR::ABL1'],['Nilotinib'],"if a patient with chronic myeloid leukemia, bcr-abl1+ cancer has bcr::abl1, what therapy is recommended?"
630,634,Chronic Myelogenous Leukemia,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),philadelphia chromosome-positive chronic myelogenous leukemia,['BCR::ABL1'],['Asciminib'],"if a patient with philadelphia chromosome-positive chronic myelogenous leukemia cancer has bcr::abl1, what therapy is recommended?"
631,635,Head and Neck Squamous Cell Carcinoma,head and neck squamous cell cancer,head and neck squamous cell carcinoma,['PD-L1 (CPS) >= 1'],['Pembrolizumab'],"if a patient with head and neck squamous cell carcinoma cancer has pd-l1 (cps) >= 1, what therapy is recommended?"
632,636,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR somatic variants'],['Datopotamab deruxtecan'],"if a patient with non-small cell lung cancer cancer has egfr somatic variants, what therapy is recommended?"
633,637,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR Exon 19 (Deletion)'],['Datopotamab deruxtecan'],"if a patient with non-small cell lung cancer cancer has egfr exon 19 (deletion), what therapy is recommended?"
634,638,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.L858R'],['Datopotamab deruxtecan'],"if a patient with non-small cell lung cancer cancer has egfr p.l858r, what therapy is recommended?"
635,639,Non-Small Cell Lung Cancer,non-small cell lung cancer,non-small cell lung cancer,['EGFR p.T790M'],['Datopotamab deruxtecan'],"if a patient with non-small cell lung cancer cancer has egfr p.t790m, what therapy is recommended?"
636,640,Invasive Breast Carcinoma,non-small cell lung cancer,invasive breast carcinoma,['EGFR Exon 20 (Insertion)'],['Datopotamab deruxtecan'],"if a patient with invasive breast carcinoma cancer has egfr exon 20 (insertion), what therapy is recommended?"
637,641,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['HER2-negative', 'ER positive']",['Datopotamab deruxtecan'],"if a patient with invasive breast carcinoma cancer has her2-negative, er positive, what therapy is recommended?"
638,642,Non-Small Cell Lung Cancer,breast cancer,non-small cell lung cancer,"['PR positive', 'HER2-negative']",['Datopotamab deruxtecan'],"if a patient with non-small cell lung cancer cancer has pr positive, her2-negative, what therapy is recommended?"
639,643,Invasive Breast Carcinoma,breast cancer,invasive breast carcinoma,"['PR positive', 'HER2-negative', 'ER positive']",['Datopotamab deruxtecan'],"if a patient with invasive breast carcinoma cancer has pr positive, her2-negative, er positive, what therapy is recommended?"
640,644,Non-Small Cell Lung Cancer,non-small cell lung cancer (NSCLC),non-small cell lung cancer,['EGFR Exon 20 (Insertion)'],['Sunvozertinib'],"if a patient with non-small cell lung cancer cancer has egfr exon 20 (insertion), what therapy is recommended?"
641,645,Lung Non-Squamous Non-Small Cell Carcinoma,non-squamous non-small cell lung cancer,lung non-squamous non-small cell carcinoma,['ERBB2 TKD activating variants'],['Zongertinib'],"if a patient with lung non-squamous non-small cell carcinoma cancer has erbb2 tkd activating variants, what therapy is recommended?"
